Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
Early recurrence in complete resected non-small cell lung cancer patients Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017
The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
Adjuvant chemotherapy in completely resected non-small cell lung cancer: Frequency of biological markers of predictive value Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010
Prognostic factors affecting survival in advanced non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004
Correlation between parameters of quality of life in patients with non-small cell lung cancer treated by chemotherapy and radiotherapy Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007
Salvage surgery in patients with locally advanced non-small cell lung cancer – outcomes and longtime results Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Prognostic factors for unresectable non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 270s Year: 2002
Comparison of quality of life in patients with non-small cell lung cancer treated by chemotherapy or radiotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004
Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 771s Year: 2006
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Relation between ERCC1 expression in sputum and survival after cisplatin-based chemotherapy in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004
Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006